BioTuesdays

Category - Feature

Feature

Prima BioMed to get key CVac data in second half

By Len Zehr After posting positive trends in interim data, Prima BioMed (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) is focusing on two final data readouts in the second half this year from a Phase 2b clinical trial of its...

January 29, 2013
Feature

Trimel in pre-NDA meeting with FDA next month

By Len Zehr Fresh from reporting positive Phase 3 results for its CompleoTRT intranasal gel for “Low T”, Trimel Pharmaceutics (TSX:TRL) plans to meet with the FDA in February to discuss its plans for filing a new drug...

January 15, 2013